SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Lowers Price Target to $27
SVB Leerink analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and lowers the price target from $34 to $27.
Barclays Maintains Equal-Weight on Ionis Pharmaceuticals, Lowers Price Target to $40
Barclays analyst Gena Wang maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Equal-Weight and lowers the price target from $44 to $40.
Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target
Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $60 price target.
Ionis Pharmaceuticals Q4 EPS $(0.37) Beats $(0.92) Estimate, Sales $152.00M Miss $158.65M Estimate
Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.92) by 59.78 percent. This is a 126.24 percent decrease over earnings of $1.41 per share
Earnings Scheduled For February 22, 2023
Companies Reporting Before The Bell
• Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.
Ionis Pharmaceuticals’s Earnings Outlook
Ionis Pharmaceuticals (NASDAQ:IONS) is set to give its latest quarterly earnings report on Wednesday, 2023-02-22. Here’s what investors…
Analyst Says Ionis’ Additional Hereditary Angioedema Study Data Supports ‘Highly Competitive Profile’
Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced additional interim data from a Phase 2 open-label extension (OLE) study of donidalorsen for hereditary angioedema. …
SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Raises Price Target to $34
SVB Leerink analyst Joseph Schwartz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and raises the price target from $33 to $34.
SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Raises Price Target to $33
SVB Leerink analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and raises the price target from $32 to $33.
Analyst Expectations for Ionis Pharmaceuticals’s Future
Over the past 3 months, 5 analysts have published their opinion on Ionis Pharmaceuticals (NASDAQ:IONS) stock. These analysts…